A revolution in the treatment of aggressive liposarcoma by pazopanib combined with chemotherapy- A case report

Authors

  • Mehrdad Payandeh Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Afshin Karami Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Samira Rahimi Department of Hematology, Iran University of Medical Science, Tehran, Iran
  • Noorodin Karami Department of Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
  • Mehrnoush Aeinfar Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

DOI:

https://doi.org/10.15419/bmrat.v6i5.544

Keywords:

Pazopanib, Tyrosine kinase inhibitor, Pleomorphic, Liposarcoma

Abstract

Pazopanib is a new tyrosine kinase inhibitor which acts as anti-VEGF signaling and antiangiogenesis. In some countries, this drug has been approved for the treatment of advanced, or metastatic soft tissue sarcoma. Nevertheless, the efficacy of Pazopanib has not yet been proven in patients with advanced liposarcoma. We reported a rare case of advanced liposarcoma that after several courses of chemotherapy, the disease was relapsed, and CT-scan results showed lung metastasis. Therapeutic measures, including surgery and chemotherapy with pazopanib, were successful in destroying the metastatic mass in the patient's lung. Our finding provides a new therapeutic approach for pleomorphic liposarcoma.

 

Downloads

Published

2019-05-31

Issue

Vol. 6 No. 5 (2019)

Section

Case report

License

Copyright The Author(s) 2017. This article is published with open access by BioMedPress. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0) which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. 

How to Cite

A revolution in the treatment of aggressive liposarcoma by pazopanib combined with chemotherapy- A case report. (2019). Biomedical Research and Therapy, 6(5), 3180-3183. https://doi.org/10.15419/bmrat.v6i5.544